Gossamer Bio (NASDAQ: GOSS) expects to submit a US new drug application for seralutinib in pulmonary arterial hypertension by September 2026 following discussions with the Food and Drug Administration. The company is simultaneously reclaiming worldwide rights to the therapy, restructuring its debt and preparing for a potential reverse stock split as it approaches a consequential regulatory stage.
Key Highlights
- Gossamer Bio (NASDAQ: GOSS) expects to file the seralutinib NDA by September 2026.
- A completed FDA Pre-NDA Type B meeting clarified the planned regulatory submission.
- The termination of the Chiesi collaboration returns full global seralutinib rights to Gossamer Bio (NASDAQ: GOSS).
- A convertible-note exchange is expected to reduce total debt by approximately $115.9 million.
- Second-quarter cash and marketable securities totalled $57 million.
Seralutinib NDA Filing Moves Towards September 2026
Gossamer Bio (NASDAQ: GOSS) remains on schedule to submit a new drug application for seralutinib in pulmonary arterial hypertension by September 2026. The timetable follows a successful Pre-NDA Type B meeting with the US Food and Drug Administration, an important procedural step used to align the proposed application with regulatory expectations.
The planned filing places seralutinib at the centre of Gossamer Bio’s (NASDAQ: GOSS) near-term strategy. PAH is a progressive condition characterised by elevated pressure in the pulmonary arteries, creating demand for therapies capable of addressing the biological mechanisms underlying vascular remodelling rather than focusing solely on symptom management.
Chiesi Exit Restores Full Global Seralutinib Rights
Gossamer Bio (NASDAQ: GOSS) and privately held Chiesi Farmaceutici have agreed to terminate their collaboration covering seralutinib. Under the settlement, Gossamer Bio (NASDAQ: GOSS) will recover full worldwide development and commercial rights, while Chiesi Farmaceutici will receive $5 million and a capped royalty on future sales.
The arrangement gives Gossamer Bio (NASDAQ: GOSS) greater control over regulatory, commercial and partnering decisions. However, it also concentrates future development expenditure and execution risk within the company. Any commercial value will remain dependent on regulatory review, manufacturing readiness and successful market access.
Debt Reduction Strengthens the Capital Structure
Shareholders also approved an exchange of convertible notes that is expected to reduce Gossamer Bio’s (NASDAQ: GOSS) total debt by approximately $115.9 million. The restructuring should lower balance-sheet leverage as the company approaches its NDA submission, although the transaction’s full effect will depend on its terms and any resulting equity dilution.
Investors additionally authorised a reverse stock split. Such measures can support compliance with Nasdaq listing requirements but do not alter the company’s underlying enterprise value or operating fundamentals.
Gossamer Bio (NASDAQ: GOSS) ended the second quarter of 2026 with $57 million in cash, cash equivalents and marketable securities. This liquidity must support regulatory preparation and corporate operations, leaving funding requirements a material consideration as seralutinib advances.



_11_19_2026_12_45_47_957380.jpg)
_11_19_2026_12_45_58_729375.jpg)

Please wait processing your request...